Already a Bloomberg.com user?
Sign in with the same account.
WOODCLIFF LAKE, N.J. (AP) — Affiliates of private investment firm TPG have completed their $1.84 billion acquisition of generic drug maker Par Pharmaceutical.
The companies announced the deal in July, saying that TPG would pay $50 per share.
Shares of Par Pharmaceutical Cos., based in Woodcliff Lake, N.J., are set to cease trading on the New York Stock Exchange since it will be a private company.